<DOC>
	<DOCNO>NCT00274274</DOCNO>
	<brief_summary>This trial conduct Europe . This trial aim comparison efficacy safety Insulin Aspart , give fix flexible supplementary insulin therapy , without Insulin Detemir plus Metformin , need , subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Fixed Flexible Supplementary Insulin Therapy Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 Diabetes 6 month Treatment 1 oral antidiabetic drug insulin , combination 3 month Body Mass Index ( BMI ) less equal 40 kg/m2 HbA1c 7.011.0 % Treatment short act insulin ( ) longer 10 day Current treatment TZDs . A TZD medication must stop least 14 day randomization Proliferative retinopathy maculopathy require acute laser treatment within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>